Diabetech - Diabetes Tech, Research, News

Gary and I take on one of the most important skills in modern diabetes management: understanding and using your data. We break down how to analyze CGM and pump data to identify patterns, trends, and problem areas without getting overwhelmed by numbers. The conversation covers basal insulin, bolus timing, insulin to carb ratios, correction factors, and what metrics like time in range and glucose variability actually tell you about your settings. We also discuss when to make adjustments on your own and when to involve a diabetes educator.   Learn about the Eversense 365 CGM   Learn about Omnipod 5 (today's sponsor)*   Learn About Integrated Diabetes (Gary’s Practice)   Send in YOUR questions!   Join the Diabetech Newsletter   Follow Diabetech: Instagram | Tik Tok | YouTube | Facebook | Threads   DISCLAIMER: This podcast is not medical advice and is for educational purposes only. Always consult with your doctor before making changes to your health care.    *10-day trial eligibility may vary. Full terms and conditions apply. Visit omnipod.com/diabetech for clinical disclaimers, terms and important safety information. The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.

Using biometrics like heart rate, stress, and activity to automate insulin delivery in real time, Rheos is a next-generation AID system designed to learn and adapt directly from the body. I sit down with Jonathan Fitch, Founder of GlucoSense, to explore how this settings-free, AI-powered AID system uses wearable data to continuously adapt insulin needs throughout the day. We get into features like logging meals by photo or voice, planning workouts through an in-app LLM, and how the system dynamically adjusts dosing based on real physiological signals. Jonathan also shares how a life-threatening seizure during college pushed him to rethink diabetes automation—and how that experience shaped Rheos’ goal of dramatically reducing the daily management burden.   Learn about the Eversense 365 CGM   T1D Exchange Registry Sign up  (US residents only)   Join the Diabetech Newsletter   Follow Diabetech: Instagram | Tik Tok | YouTube | Facebook | Threads   DISCLAIMER: This podcast is not medical advice and is for educational purposes only. Always consult with your doctor before making changes to your health care.    *10-day trial eligibility may vary. Full terms and conditions apply. Visit omnipod.com/diabetech for clinical disclaimers, terms and important safety information. The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.

Insulin pump access in the U.S. is changing fast, with more companies moving to pharmacy benefits and making it easier than ever for people with diabetes to start—or switch—systems. While this shift brings more choice and flexibility, it’s also exposing serious challenges around safety, training, and continuity of care. As AID systems become more complex and less interchangeable, switching pumps isn’t as simple as transferring settings anymore. In this episode, Diana Isaacs, PharmD, CDCES joins me to break down what’s really happening as pump transitions become more frequent and why both users and healthcare providers are feeling the strain. We talk about why confusion is increasing, where transitions often go wrong, and what needs to change to make pump switching safer and more effective for everyone.   Learn about the Eversense 365 CGM   Sell your collection to Markest    Join the Diabetech Newsletter   Follow Diabetech: Instagram | Tik Tok | YouTube | Facebook | Threads   DISCLAIMER: This podcast is not medical advice and is for educational purposes only. Always consult with your doctor before making changes to your health care. 

Gary Scheiner, a certified diabetes care and education specialist and founder of Integrated Diabetes Services, shares his expertise on optimizing basal insulin for better glucose stability. He explains the critical role of basal insulin in managing liver glucose and how incorrect settings can lead to highs and lows. Listeners learn about common misconceptions, the effects of various factors on basal needs, and practical tips for testing and adjusting insulin. Gary also highlights the advantages of advanced diabetes technology like pumps and automated systems.

2025 delivered major innovations in diabetes tech as well as surprising twists and today we explore the wins, the fails, and what these trends mean for people living with diabetes. I sit down with Kamil Armacky of Nerdabetic to unpack everything from Libre 3 Plus expanding pump integrations, updates and sensor recall, to Dexcom’s new 15-day sensor and how the community feels about it. We also dive into major industry shifts, including Medtronic Diabetes separating to form MiniMed, Omnipod’s roadmap for Omnipod 6 and beyond, and Eversense taking full control of its implantable business. This is a big one!   Learn about Omnipod 5 (today's sponsor)*   Join the Diabetech Newsletter   Follow Diabetech: Instagram | Tik Tok | YouTube | Facebook | Threads   DISCLAIMER: This podcast is not medical advice and is for educational purposes only. Always consult with your doctor before making changes to your health care.    *10-day trial eligibility may vary. Full terms and conditions apply. Visit omnipod.com/diabetech for clinical disclaimers, terms and important safety information. The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.

In this conversation, Pablo Medina, a medical graduate and software engineer diagnosed with LADA, shares his journey from misdiagnosis to innovation. He created an iPhone app to track insulin patch usage after struggling with existing diabetes tech. Pablo discusses his experiences with devices like InPen and Omnipod 5, highlighting the gaps he encountered. He reveals the challenges of app development and advocates for better CGM interoperability. His story is a testament to how patient-driven solutions can shape diabetes technology.

Laura Endres, Senior VP at Medtronic Diabetes, shares exciting insights about the new Instinct CGM. This 15-day, no-calibration sensor integrates seamlessly with the 780G insulin pump and highlights Medtronic's partnership with Abbott. Laura offers a live demo, showcasing its user-friendly applicator. She compares Instinct with Simplera, discusses future pump innovations, and emphasizes the importance of customer choice in sensor technology. Plus, get a glimpse of upcoming features like customizable alerts and global rollout plans!

On our new show Optimizing Diabetes Tech (ODT) my co-host Gary Scheiner CDCES and I discuss how people with diabetes can take full advantage of their continuous glucose monitors to make managing Diabetes easier and safer. We get into how to react to alarms, adjust settings, and the features you need to know about. We also answer your questions about CGMs.   Learn about Omnipod 5 (today's sponsor)*   Learn About Integrated Diabetes Services (Gary’s Practice)   Send us YOUR questions!   Join the Diabetech Newsletter   Follow Diabetech: Instagram | Tik Tok | YouTube | Facebook | Threads   DISCLAIMER: This podcast is not medical advice and is for educational purposes only. Always consult with your doctor before making changes to your health care.    *10-day trial eligibility may vary. Full terms and conditions apply. Visit omnipod.com/diabetech for clinical disclaimers, terms and important safety information. The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.

This week, cybersecurity expert Josiah Dykstra shares insights from his career at the NSA and his life with type 1 diabetes. He discusses the stringent security measures around medical devices in classified settings and why standalone devices, like Dexcom receivers, are crucial. Josiah opens up about his initial fears of pump hacking, his decision to embrace automated insulin delivery, and the FDA's evolving regulations on medical tech. He emphasizes the importance of personal cybersecurity and urges patients to advocate for stronger security measures.

Dr. David Ahn, chief of diabetes services at the Mary and Dick Allen Diabetes Center, explores the future of insulin pumps. He discusses the competitive landscape between companies like Omnipod and Tandem, the importance of seven-day wearable infusion sets, and the evolving algorithms for insulin delivery. Ahn highlights the potential for dual-hormone systems and addresses the future of closed-loop systems. The conversation delves into innovations like Beta Bionics' reusable Mint pump and the need for more user-friendly technology in diabetes management.